ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the successful initiation of a Phase Ib clinical trial with the first patient dosed using their drugs IMM2510 and IMM27M for advanced solid tumors. IMM2510, a bispecific molecule, targets VEGF and PD-L1 to inhibit tumor growth and stimulate immune response, while IMM27M, a CTLA-4 antibody, aims to enhance T-cell antitumor activity by targeting Treg cells in the tumor microenvironment. The company cautions that the development and market success of these drugs is not guaranteed.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.
